Pharvis Korea Pharm

Pharvis Korea Pharm is a South Korean pharmaceutical company founded in 1976, specializing in the development, manufacturing, and distribution of a wide range of healthcare products. The company's portfolio includes prescription drugs (ETC), over-the-counter (OTC) medicines, contrast media, medical devices, and health supplements, with a strong focus on drug formulation research and incrementally modified drugs (IMDs). Pharvis operates a central research institute and multiple manufacturing facilities, providing contract development and manufacturing organization (CDMO) services to global partners. Its R&D pipeline features innovative candidates such as PM601, a GPR119 agonist for non-alcoholic steatohepatitis (NASH), and BLT inhibitors for inflammatory diseases. The company maintains strategic partnerships with international firms like Ginsana and NOUVAG to exclusively supply specialized medical products in the Korean market.